ClinicalTrials.gg
CompletedNCT00347425Updated May 21, 2008

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

A Phase 3 interventional study of Aripiprazole and Olanzapine in Schizophrenia and Schizoaffective Disorder, sponsored by Solvay Pharmaceuticals. Completed at 122 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-05-21.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
37th of 125
286 · median 130
Started
2006
with 7 others
Phase 3
34 of 126
1 open now
Registered
37th of 126
by date

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 37th largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2006, is one of 34 in phase 3, and was the 37th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

03

Conditions studied

  • Schizophrenia and Schizoaffective Disorder

Keywords

  • Switch Study
  • Schizophrenia
  • Atypical Antipsychotics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, 18-65 years, meeting TR diagnosis of Schizophrenia or Schizoaffective Disorder for whom a switch is indicated

Exclusion criteria

Exclusion Criteria:

  • Acutely psychotic or with a current Axis I primary psychiatric diagnosis other than schizophrenia or schizoaffective disorder based on TR criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Other
    A

    Drug: Aripiprazole · Drug: Olanzapine · Drug: Risperidone · Drug: Quetiapine · Drug: Ziprasidone

  • Other
    B

    Drug: Aripiprazole · Drug: Olanzapine · Drug: Risperidone · Drug: Quetiapine · Drug: Ziprasidone

Interventions

  • Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

  • Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

  • Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

  • Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

  • Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

  • Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

  • Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

  • Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

  • Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

  • Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

06

What researchers measure

Primary outcomes

  1. Successful switch defined as those who complete the 4 weeks core study with no worsening of 2 successive post baseline assessments on the CGIS, exacerbation of EPS, or cardiovascular risk factors (body weight and fasting triglycerides) from baseline.

    Time frame: 4 weeks

Secondary outcomes

  1. Adverse events

    Time frame: 4 weeks

  2. Adverse events

    Time frame: 26 weeks

07

Study locations

122 sites
  • Site 148
    Birmingham, Alabama, United States
  • Site 194
    Little Rock, Arkansas, United States
  • Site 178
    Anaheim, California, United States
  • Site 167
    Cerritos, California, United States
  • Site 189
    Cerritos, California, United States
  • Site 183
    Culver City, California, United States
  • Site 140
    Garden Grove, California, United States
  • Site 162
    La Palma, California, United States
  • Site 190
    Long Beach, California, United States
  • Site 173
    Oceanside, California, United States
  • Site 175
    Paramount, California, United States
  • Site 136
    Pasadena, California, United States
  • Site 184
    Sacramento, California, United States
  • Site 152
    San Diego, California, United States
  • Site 186
    San Diego, California, United States
  • Site 133
    Santa Ana, California, United States
  • Site 171
    Torrance, California, United States
  • Site 197
    Boca Raton, Florida, United States
  • Site 156
    Gainesville, Florida, United States
  • Site 188
    Hialeah, Florida, United States
  • Site 193
    Jacksonville, Florida, United States
  • Site 154
    Miami, Florida, United States
  • Site 163
    North Miami, Florida, United States
  • Site 168
    North Miami, Florida, United States
  • Site 166
    Orange City, Florida, United States
  • Site 124
    Orlando, Florida, United States
  • Site 187
    Tampa, Florida, United States
  • Site 161
    Atlanta, Georgia, United States
  • Site 128
    Augusta, Georgia, United States
  • Site 122
    Decatur, Georgia, United States
  • Site 174
    Chicago, Illinois, United States
  • Site 164
    Indianapolis, Indiana, United States
  • Site 172
    Lake Charles, Louisiana, United States
  • Site 182
    Shreveport, Louisiana, United States
  • Site 121
    Glen Burnie, Maryland, United States
  • Site 159
    Detroit, Michigan, United States
  • Site 153
    Minneapolis, Minnesota, United States
  • Site 145
    St. Charles, Missouri, United States
  • Site 130
    St. Louis, Missouri, United States
  • Site 141
    St. Louis, Missouri, United States
  • Site 142
    Clementon, New Jersey, United States
  • Site 180
    Kenilworth, New Jersey, United States
  • Site 129
    Albuquerque, New Mexico, United States
  • Site 131
    Brooklyn, New York, United States
  • Site 181
    Cedarhurst, New York, United States
  • Site 169
    Jamaica, New York, United States
  • Site 195
    New York, New York, United States
  • Site 147
    Staten Island, New York, United States
  • Site 127
    Chagrin Falls, Ohio, United States
  • Site 176
    Cincinnati, Ohio, United States
  • Site 191
    Oklahoma City, Oklahoma, United States
  • Site 146
    Philadelphia, Pennsylvania, United States
  • Site 179
    Philadelphia, Pennsylvania, United States
  • Site 196
    Sioux Falls, South Dakota, United States
  • Site 134
    Memphis, Tennessee, United States
  • Site 170
    Memphis, Tennessee, United States
  • Site 177
    Austin, Texas, United States
  • Site 185
    Conroe, Texas, United States
  • Site 126
    Houston, Texas, United States
  • Site 151
    San Antonio, Texas, United States
  • Site 138
    Richmond, Virginia, United States
  • Site 198
    Spokane, Washington, United States
  • Site 165
    Huntington, West Virginia, United States
  • Site 302
    Buenos Aires, Argentina
  • Site 305
    Buenos Aires, Argentina
  • Site 306
    Cordoba, Argentina
  • Site 307
    La Plata, Argentina
  • Site 301
    Mendoza, Argentina
  • Site 304
    Mendoza, Argentina
  • Site 308
    Mendoza, Argentina
  • Site 303
    Rosario, Argentina
  • Site 116
    Chatham, Ontario, Canada
  • Site 117
    Mississauga, Ontario, Canada
  • Site 100
    Calgary, Canada
  • Site 101
    Claresholm, Canada
  • Site 110
    Halifax, Canada
  • Site 111
    Hull, Canada
  • Site 107
    Kelowna, Canada
  • Site 109
    Kingston, Canada
  • Site 115
    Markham, Canada
  • Site 112
    Medicine Hat, Canada
  • Site 108
    Orleans, Canada
  • Site 106
    Ottawa, Canada
  • Site 104
    Prince Albert, Canada
  • Site 102
    Sherbrooke, Canada
  • Site 114
    Victoria, Canada
  • Site 113
    Winnipeg, Canada
  • Site 235
    Bolonska, Czech Republic
  • Site 234
    Jablonova, Czech Republic
  • Site 216
    Litomerice, Czech Republic
  • Site 233
    Na Markvartce, Czech Republic
  • Site 213
    Olomouc, Czech Republic
  • Site 214
    Plzen, Czech Republic
  • Site 217
    Prague, Czech Republic
  • Site 215
    Praha, Czech Republic
  • Site 236
    Rejskovo namesti, Czech Republic
  • Site 231
    Paldksi Mnt, Estonia
  • Site 229
    Tartu, Estonia
  • Site 230
    Voru, Estonia
  • Site 202
    Clermont Ferrand, France

Showing the first 100 of 122 sites across 9 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2006
First posted
Jul 4, 2006
Start
Dec 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
May 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00347425
First posted
Jul 4, 2006
Start date
Dec 2006
Primary completion
Feb 2008
Completion
Feb 2008
Last update
May 21, 2008

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Olanzapine · Risperidone · Quetiapine · Ziprasidone

Start the discussion